Bausch Health Companies Inc. (NYSE: BHC), a key player in the healthcare sector, has piqued investor interest with its diverse portfolio and substantial growth potential. Headquartered in Laval, Canada, Bausch Health engages in the development, manufacturing, and marketing of a broad array of pharmaceutical and medical device products. The company’s operations span across multiple therapeutic areas, including gastroenterology, neurology, dermatology, and eye health, among others.

At a current share price of $5.98, Bausch Health is trading near the lower end of its 52-week range of $4.32 to $8.34. Despite this, analysts see a significant potential upside of 31.39%, with the average target price set at $7.86. This optimism is…